SCHEMBL17633643

SCHEMBL17633643

O=C1Nc2cccc(F)c2OC1c1ccc(C(F)(F)F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
CCKAR P32238 2/20 0.39
CCKBR P32239 2/20 0.39
BRD4 O60885 2/20 0.38
CA2 P00918 1/20 0.38
GSK3B P49841 1/20 0.36
PARP1 P09874 1/20 0.35
PARP2 Q9UGN5 1/20 0.35
TP53 P04637 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TRPM8 Q7Z2W7 3/20 0.34
F7 P08709 1/20 0.33
F3 P13726 1/20 0.33
PGR P06401 1/20 0.33
CREBBP Q92793 1/20 0.32
HSP90AA1 P07900 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17633644 0.86 PBRM1 (0.40) MAPTKMT2AMEN1ALDH1A1GAA
SCHEMBL17634295 0.86 MAPT (0.39) MAPTKMT2AMEN1ALDH1A1GAA
SCHEMBL17634084 0.80 PARP1 (0.49) MAPTKMT2AMEN1ALDH1A1GAA
SCHEMBL17634184 0.75 CA2 (0.37) KMT2AMEN1ALDH1A1BRD4CA2
SCHEMBL17634231 0.74 BRD4 (0.47) KMT2ABRD4CA2TP53PGR
SCHEMBL17634285 0.74 BRD4 (0.40) KMT2AMEN1BRD4CA2GSK3B
SCHEMBL17633645 0.72 KMT2A (0.40) MAPTKMT2AMEN1ALDH1A1GAA
SCHEMBL17634136 0.72 KMT2A (0.43) MAPTKMT2AMEN1ALDH1A1GAA
SCHEMBL18128151 0.71 PARP1 (0.56) BRD4PARP1CREBBP
SCHEMBL18128266 0.71 PARP1 (0.56) BRD4PARP1CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3197900-B1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME (US) 2020-02-12 EP disclosed
US-9969752-B2 Inhibitors of HIF prolyl hydroxylase MERCK SHARP & DOHME CORP. (US) 2018-05-15 US disclosed
US-20170233412-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME CORP. (US) 2017-08-17 US disclosed
EP-3197900-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE Merck Sharp & Dohme Corp. (US) 2017-08-02 EP disclosed
WO-2016045127-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME CORP. (US) 2016-03-31 WO disclosed
WO-2016049099-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME CORP. (US) 2016-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233412-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE HIF1AN, HIF1A, EGLN2 MAPT 3798/4885KMT2A 940/4885MEN1 4300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.